{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T04:05:34Z","timestamp":1745899534994,"version":"3.40.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,28]]},"DOI":"10.7759\/cureus.83133","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T15:52:43Z","timestamp":1745855563000},"source":"Crossref","is-referenced-by-count":0,"title":["Schematic Assessment of Metabolic Signatures of Non-alcoholic Fatty Liver Disease by Bridging Endocrinology and Internal Medicine: A Precision Therapy-Based Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Syed Muzaffar","family":"Abbas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeeshan","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nimra","family":"Asghar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahnoor","family":"Shabbir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Armaghan","family":"Akhlaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafiz Muhammad Faizan","family":"Mughal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asma","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul Eizad","family":"Asif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehsan Ul Haq","family":"Mzahri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.70020","article-title":"Addressing the high and rising global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH): from the growing prevalence to payors' perspective","volume":"61","author":"Younossi ZM","year":"2025","unstructured":"Younossi ZM, Razavi H, Sherman M, et al.. Addressing the high and rising global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH): from the growing prevalence to payors' perspective. Aliment Pharmacol Ther. 2025, 61:1467-78. 10.1111\/apt.70020","journal-title":"Aliment Pharmacol Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.11.029","article-title":"Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease","volume":"78","author":"Sanyal AJ","year":"2023","unstructured":"Sanyal AJ, Williams SA, Lavine JE, et al.. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2023, 78:693-703. 10.1016\/j.jhep.2022.11.029","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00754-7","article-title":"Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment","volume":"20","author":"Llovet JM","year":"2023","unstructured":"Llovet JM, Willoughby CE, Singal AG, et al.. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nat Rev Gastroenterol Hepatol. 2023, 20:487-503. 10.1038\/s41575-023-00754-7","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18105227","article-title":"Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors","volume":"18","author":"Juanola O","year":"2021","unstructured":"Juanola O, Mart\u00ednez-L\u00f3pez S, Franc\u00e9s R, G\u00f3mez-Hurtado I. Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors. Int J Environ Res Public Health. 2021, 18:10.3390\/ijerph18105227","journal-title":"Int J Environ Res Public Health"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.971561","article-title":"Application of metabolomics in the diagnosis of non-alcoholic fatty liver disease and the treatment of traditional Chinese medicine","volume":"13","author":"Shao M","year":"2022","unstructured":"Shao M, Lu Y, Xiang H, Wang J, Ji G, Wu T. Application of metabolomics in the diagnosis of non-alcoholic fatty liver disease and the treatment of traditional Chinese medicine. Front Pharmacol. 2022, 13:971561. 10.3389\/fphar.2022.971561","journal-title":"Front Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.hbpd.2021.05.008","article-title":"LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver","volume":"20","author":"Wang ZH","year":"2021","unstructured":"Wang ZH, Zheng KI, Wang XD, et al.. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver. Hepatobiliary Pancreat Dis Int. 2021, 20:452-9. 10.1016\/j.hbpd.2021.05.008","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/lci2.25","article-title":"Salivary metabolites are promising non-invasive biomarkers of hepatocellular carcinoma and chronic liver disease","volume":"2","author":"Hershberger CE","year":"2021","unstructured":"Hershberger CE, Rodarte AI, Siddiqi S, et al.. Salivary metabolites are promising non-invasive biomarkers of hepatocellular carcinoma and chronic liver disease. Liver Cancer Int. 2021, 2:33-44. 10.1002\/lci2.25","journal-title":"Liver Cancer Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154457","article-title":"Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression","volume":"116","author":"Nimer N","year":"2021","unstructured":"Nimer N, Choucair I, Wang Z, et al.. Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression. Metabolism. 2021, 116:154457. 10.1016\/j.metabol.2020.154457","journal-title":"Metabolism"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01348","article-title":"Targeted molecular analysis in adrenocortical carcinomas: a strategy toward improved personalized prognostication","volume":"103","author":"Lippert J","year":"2018","unstructured":"Lippert J, Appenzeller S, Liang R, et al.. Targeted molecular analysis in adrenocortical carcinomas: a strategy toward improved personalized prognostication. J Clin Endocrinol Metab. 2018, 103:4511-23. 10.1210\/jc.2018-01348","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100477","article-title":"Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease","volume":"4","author":"McGlinchey AJ","year":"2022","unstructured":"McGlinchey AJ, Govaere O, Geng D, et al.. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. JHEP Rep. 2022, 4:100477. 10.1016\/j.jhepr.2022.100477","journal-title":"JHEP Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1128\/msystems.01148-24","article-title":"Multi-omics analyses of the gut microbiota and metabolites in children with metabolic dysfunction-associated steatotic liver disease","volume":"10","author":"Du L","year":"2025","unstructured":"Du L, Zhang K, Liang L, et al.. Multi-omics analyses of the gut microbiota and metabolites in children with metabolic dysfunction-associated steatotic liver disease. mSystems. 2025, 10:e0114824. 10.1128\/msystems.01148-24","journal-title":"mSystems"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32427","article-title":"Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles","volume":"76","author":"Mart\u00ednez-Arranz I","year":"2022","unstructured":"Mart\u00ednez-Arranz I, Bruzzone C, Noureddin M, et al.. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. Hepatology. 2022, 76:1121-34. 10.1002\/hep.32427","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/livers5010012","article-title":"A metabolomics-based approach for diagnosing NAFLD and identifying its pre-condition along the potential disease spectrum","volume":"5","author":"Nojima M","year":"2025","unstructured":"Nojima M, Kimura T, Aoki Y, et al.. A metabolomics-based approach for diagnosing NAFLD and identifying its pre-condition along the potential disease spectrum. Livers. 2025, 5:12. 10.3390\/livers5010012","journal-title":"Livers"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2024.01.007","article-title":"Distinct changes in serum metabolites and lipid species in the onset and progression of NAFLD in Obese Chinese","volume":"23","author":"Chen J","year":"2024","unstructured":"Chen J, Lu RS, Diaz-Canestro C, et al.. Distinct changes in serum metabolites and lipid species in the onset and progression of NAFLD in Obese Chinese. Comput Struct Biotechnol J. 2024, 23:791-800. 10.1016\/j.csbj.2024.01.007","journal-title":"Comput Struct Biotechnol J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12090881","article-title":"Association of metabolic signatures with nonalcoholic fatty liver disease in pediatric population","volume":"12","author":"Chae W","year":"2022","unstructured":"Chae W, Lee KJ, Huh KY, Moon JS, Ko JS, Cho JY. Association of metabolic signatures with nonalcoholic fatty liver disease in pediatric population. Metabolites. 2022, 12:10.3390\/metabo12090881","journal-title":"Metabolites"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/nu14091773","article-title":"A low glycemic index mediterranean diet combined with aerobic physical activity rearranges the gut microbiota signature in NAFLD patients","volume":"14","author":"Calabrese FM","year":"2022","unstructured":"Calabrese FM, Disciglio V, Franco I, et al.. A low glycemic index mediterranean diet combined with aerobic physical activity rearranges the gut microbiota signature in NAFLD patients. Nutrients. 2022, 14:10.3390\/nu14091773","journal-title":"Nutrients"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/nu16081235","article-title":"Circulatory metabolite ratios as indicators of lifestyle risk factors based on a Greek NAFLD case-control study","volume":"16","author":"Fotakis C","year":"2024","unstructured":"Fotakis C, Amanatidou AI, Kafyra M, Andreou V, Kalafati IP, Zervou M, Dedoussis GV. Circulatory metabolite ratios as indicators of lifestyle risk factors based on a Greek NAFLD case-control study. Nutrients. 2024, 16:10.3390\/nu16081235","journal-title":"Nutrients"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-023-01878-0","article-title":"Identification and immunological characterization of lipid metabolism-related molecular clusters in nonalcoholic fatty liver disease","volume":"22","author":"Liu J","year":"2023","unstructured":"Liu J, Li Y, Ma J, Wan X, Zhao M, Zhang Y, Shang D. Identification and immunological characterization of lipid metabolism-related molecular clusters in nonalcoholic fatty liver disease. Lipids Health Dis. 2023, 22:124. 10.1186\/s12944-023-01878-0","journal-title":"Lipids Health Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-92972-z","article-title":"Identification and verification of biomarkers associated with arachidonic acid metabolism in non-alcoholic fatty liver disease","volume":"15","author":"Li J","year":"2025","unstructured":"Li J, Su WW, Wang ZL, Ji XF, Wang JW, Wang K. Identification and verification of biomarkers associated with arachidonic acid metabolism in non-alcoholic fatty liver disease. Sci Rep. 2025, 15:8521. 10.1038\/s41598-025-92972-z","journal-title":"Sci Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001227","article-title":"Utility of metabolomic biomarkers to identify nonalcoholic fatty liver disease in liver transplant recipients","volume":"7","author":"Mowry CJ","year":"2021","unstructured":"Mowry CJ, Alonso C, Iruarrizaga-Lejarreta M, Ortiz P, Levitsky J, Rinella M. Utility of metabolomic biomarkers to identify nonalcoholic fatty liver disease in liver transplant recipients. Transplant Direct. 2021, 7:e784. 10.1097\/TXD.0000000000001227","journal-title":"Transplant Direct"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s11306-020-01756-1","article-title":"Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis","volume":"17","author":"Masarone M","year":"2021","unstructured":"Masarone M, Troisi J, Aglitti A, et al.. Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis. Metabolomics. 2021, 17:12. 10.1007\/s11306-020-01756-1","journal-title":"Metabolomics"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10061444","article-title":"The emerging role of branched-chain amino acids in liver diseases","volume":"10","author":"Lo EK","year":"2022","unstructured":"Lo EK, Felicianna, Xu JH, Zhan Q, Zeng Z, El-Nezami H. The emerging role of branched-chain amino acids in liver diseases. Biomedicines. 2022, 10:10.3390\/biomedicines10061444","journal-title":"Biomedicines"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2023.101432","article-title":"Concise review of lipidomics in nonalcoholic fatty liver disease","volume":"49","author":"B\u00e9land-Bonenfant S","year":"2023","unstructured":"B\u00e9land-Bonenfant S, Rouland A, Petit JM, Verg\u00e8s B. Concise review of lipidomics in nonalcoholic fatty liver disease. Diabetes Metab. 2023, 49:101432. 10.1016\/j.diabet.2023.101432","journal-title":"Diabetes Metab"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-331740","article-title":"Artificial intelligence applied to 'omics data in liver disease: towards a personalised approach for diagnosis, prognosis and treatment","volume":"74","author":"Ghosh S","year":"2025","unstructured":"Ghosh S, Zhao X, Alim M, Brudno M, Bhat M. Artificial intelligence applied to 'omics data in liver disease: towards a personalised approach for diagnosis, prognosis and treatment. Gut. 2025, 74:295-311. 10.1136\/gutjnl-2023-331740","journal-title":"Gut"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-023-05110-1","article-title":"Integrated multi-omic analysis identifies fatty acid binding protein 4 as a biomarker and therapeutic target of ischemia-reperfusion injury in steatotic liver transplantation","volume":"81","author":"Yang M","year":"2024","unstructured":"Yang M, Shu W, Zhai X, et al.. Integrated multi-omic analysis identifies fatty acid binding protein 4 as a biomarker and therapeutic target of ischemia-reperfusion injury in steatotic liver transplantation. Cell Mol Life Sci. 2024, 81:83. 10.1007\/s00018-023-05110-1","journal-title":"Cell Mol Life Sci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/biom12010056","article-title":"Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives","volume":"12","author":"Vallianou N","year":"2021","unstructured":"Vallianou N, Christodoulatos GS, Karampela I, et al.. Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives. Biomolecules. 2021, 12:10.3390\/biom12010056","journal-title":"Biomolecules"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2021.100149","article-title":"Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD)","volume":"12","author":"Zarghamravanbakhsh P","year":"2021","unstructured":"Zarghamravanbakhsh P, Frenkel M, Poretsky L. Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD). Metabol Open. 2021, 12:100149. 10.1016\/j.metop.2021.100149","journal-title":"Metabol Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/362391-schematic-assessment-of-metabolic-signatures-of-non-alcoholic-fatty-liver-disease-by-bridging-endocrinology-and-internal-medicine-a-precision-therapy-based-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T15:52:43Z","timestamp":1745855563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/362391-schematic-assessment-of-metabolic-signatures-of-non-alcoholic-fatty-liver-disease-by-bridging-endocrinology-and-internal-medicine-a-precision-therapy-based-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.83133","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,28]]}}}